Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 2/20 | 0.51 |
| ▸ | CPB1 | P15086 | 1/20 | 0.51 |
| ▸ | CPA3 | P15088 | 1/20 | 0.51 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.44 |
| ▸ | PAM | P19021 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11834777 | 0.91 | MMP12 (0.48) | CPA1PTGS1TSHR | |
| SCHEMBL11822857 | 0.87 | PTGS1 (0.47) | MEN1HPGDKMT2APTGS1TSHR | |
| SCHEMBL9107677 | 0.86 | CPA1 (0.55) | CPA1CPB1CPA3CPB2ALPI | |
| SCHEMBL7037470 | 0.83 | MMP12 (0.47) | MEN1HPGDKMT2ATSHR | |
| SCHEMBL11837137 | 0.82 | MME (0.55) | MEN1KMT2A | |
| SCHEMBL12268109 | 0.82 | PPID (0.46) | MEN1HPGDKMT2APOLBLTA4H | |
| SCHEMBL7040817 | 0.82 | CYP1A2 (0.54) | MEN1HPGDKMT2ACYP1A2SLC15A1 | |
| SCHEMBL7290221 | 0.81 | CPA1 (0.50) | CPA1CPB1CPA3CPB2ALPI | |
| SCHEMBL11832270 | 0.79 | SRR (0.46) | CPA1PTGS1TSHR | |
| SCHEMBL11828266 | 0.79 | MMP12 (0.46) | PTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0916654-B1 | SULFONIC ESTER DERIVATIVES, PROCESS FOR PREPARING THE SAME, AND USE THEREOF | KANEKA CORP (JP) | 2005-02-23 | — | — | EP | disclosed |
| US-20030050310-A1 | Hydroxamic acid derivatives as proteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2003-03-13 | — | — | US | disclosed |
| US-6479502-B1 | TREATMENT OF DISEASES AND CONDITIONS RESPONSIVE TO MODULATION OF MATRIX METALLOPROTEINASE ACTIVITY | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1107953-A1 | HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012477-A1 | HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| US-5136076-A | Splitting of racemic 3-acetylthio-2-benzyl propionic acid by reaction with ephedrin, separation of salts, freeing of the acid and coupling with the corresponding amino acid ester | SOCIETE CIVILE BIOPROJET (FR) | 1992-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050310-A1 | Hydroxamic acid derivatives as proteinase inhibitors | MMP2, CTSH, TIMP3 | CPA1 33/4885CPB1 71/4885CPA3 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.